CRPC
Metastatic castration-resistant prostate cancer
Advertisement
177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
The combination demonstrated a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition and OR.
Final TALAPRO-2 results show talazoparib + enzalutamide significantly improves survival in patients with HRR-deficient mCRPC.
New research sheds light on the real-world outcomes of Lu-PSMA-617 in a racially diverse patient population.
Tala/enza demonstrated improvement in OS compared with enza alone as 1L treatment in patients with mCRPC.
C2D1 ctDNA fraction may be more strongly associated with rPFS and OS than baseline ctDNA fraction.
Patients with metastatic PCa are recommended to undergo both germline and somatic DNA sequencing using panel-based assays.
In the final segment, the panel emphasizes the importance of trust in the patient-provider relationship.
The panel exchanges strategies on sequencing and debates the potential of immunotherapy in prostate cancer.
In part four, the panel shares thoughts on the implications of recent trials including ARASENS, ARANOTE, and PEACE-3.
The panel discusses nuances to consider when using PSMA PET imaging, including differentiating false positives.
Experts discuss managing prostate cancer progression, risk stratification, and balancing treatment with quality of life.
Expert panel discusses diagnostic criteria, precision medicine, and PSMA imaging in managing metastatic prostate cancer.
Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.